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RNA virus vectors are attractive vaccine delivery agents capable of directing high-level gene expression without integration into host cell
DNA. However, delivery of non-encapsidated RNAviral vectors into animal cells is relatively inefficient. By introducing the tobacco mosaic virus
(TMV) origin of assembly into the RNA genome of Semliki Forest virus (SFV), we generated an SFV expression vector that could be efficiently
packaged (trans-encapsidated) in vitro by purified TMV coat protein (CP). Using cellular assays, pseudovirus disassembly, RNA replication and
reporter gene expression were demonstrated. We also evaluated the immune response to trans-encapsidated recombinant SFV carrying a model
antigen gene (β-galactosidase) in C57/B6 mice. Relative to RNA alone, vector encapsidation significantly improved the humoral and cellular
immune responses. Furthermore, reassembly with recombinant TMV CPs permitted the display of peptide epitopes on the capsid surface as either
genetic fusions or through chemical conjugation, to complement the immunoreactivity of the encapsidated RNA genetic payload. The SFV vector/
TMV CP system described provides an alternative nucleic acid delivery mechanism that is safe, easy to manufacture in vitro and that also
facilitates the generation of unique nucleic acid/protein antigen compositions.
© 2006 Elsevier Inc. All rights reserved.Keywords: Tobacco mosaic virus; Reassembly; Semliki Forest virus; Pseudovirus; Antibody response; Cellular immune response; AlphavirusIntroduction
Genetic immunization against pathogen or tumor antigens
has proven successful using DNA and modified virus vectors.
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doi:10.1016/j.virol.2006.08.040to stimulate high levels of cellular immune responses, when
compared with protein antigens of extracellular origin. The
simplest approach to gene therapy is the injection of naked
plasmid DNA, yet due to the inefficiency of cellular uptake
(Nishikawa andHuang, 2001), a high dose of plasmid is required
to stimulate immunity, which has posed a challenge for
widespread use (Hoare et al., 2005; Levy et al., 2000). Concerns
have also been raised regarding the possibility of genomic
integration and resulting cellular transformation events. Exten-
sive animal testing has indicated that the likelihood of plasmid
incorporation into host DNA is low (Martin et al., 1999; Vilalta
et al., 2005). However, a recent study (Wang et al., 2004)
evaluating strategies for improved plasmid delivery resulted in
multiple independent genomic integration events, suggesting
that a balance between efficacy and safety must be considered.
One alternative to DNA vaccination are RNA virus vectors
(Lundstrom, 2002) such as Semliki Forest virus (SFV) based
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vectors show transient persistence (Morris-Downes et al., 2001),
have a comparable or superior ability to deliver pathogen and
tumor antigen genes in animal models to either prevent or cure
disease (Lundstrom, 2002; Lundstrom, 2005) and do not
integrate into chromosomal DNA. For immunizations, the
SFV RNA can be either used directly or packaged into
recombinant replication-deficient SFV particles (Berglund et
al., 1993). The current process of manufacturing SFV particles
via transient transfection procedures is both difficult to scale and
may result in replication competent virus, although improve-
ments to the system have reduced the likelihood of recombina-
tion (Smerdou and Liljestrom, 1999). One recently reported
alternative is to encapsidate SFV-based RNA vectors using the
vesicular stomatitis virus glycoprotein (VSV-G) in place of the
SFV structural proteins, as there is no sequence homology
between VSV-G and the SFV vector genome. However, the
culture conditions for this system remain problematic (Dorange
et al., 2004). We therefore investigated alternative packaging
strategies for the SFV replicon, by employing the capsid of a
distantly related member of the alphavirus superfamily, Tobacco
mosaic virus (TMV).
To evaluate this approach, we incorporated the TMV origin
of assembly (Oa) into a SFV replicon containing the beta-
galactosidase (β-gal) reporter gene. Packaging of the RNA then
occurs simply by mixing purified coat protein (CP) with
modified SFV RNA in vitro. RNA-directed self-assembly
results in the efficient in vitro manufacturing of trans-
encapsidated SFV pseudovirus in amounts directly proportional
to RNA concentration when CP is in excess. To further expandFig. 1. RNA scaffolds compatible with TMV CP reassembly. (A) Simplified schem
assembly (Oa; Reproduced courtesy of G. Stubbs). (B) Size and structure of the + se
construct expressing β-galactosidase (SFV β-gal). (C to E) Representative electron m
were combined with various TMV CP preparations. (C) TMV genomic RNAwith U
lysine modified CP (LSB 1295.10). Scale bars represent 200 nm.this delivery system, we considered encapsidation with
recombinant CPs, to introduce functionality to the pseudovirion
capsid. As examples, the SFV replicon was combined with a
TMV CP displaying an integrin-binding motif and a CP
displaying a surface-exposed lysine. The latter facilitates the
conjugation and co-delivery of peptides or whole protein (Smith
et al., 2006) with the genetic payload, to create “bi-functional”
pseudovirion vaccine compositions. For one such bi-functional
vaccine, we complemented the encapsidated RNA with a
surface-displayed T-cell peptide epitope derived from β-gal.
Interestingly, the immune response to the combination of
nucleic acid and protein antigen was skewed completely to the
Th1 cellular response. The methods described can be easily
extended to RNA encoding any biological activity including
cytokines, chemokines, multiple target RNAs, encapsidated by
any number of CP modifications with the desired immuno-
modulatory function(s).
Results
Assembly and characterization of pseudovirions and virus-like
particles
TMV capsid formation is initiated by the interaction of CP
subassemblies with a ∼300 nt stem–loop structure internal to
the genomic RNA (the origin of assembly; Oa) that has beenwell
defined (reviewed in Butler, 1999). The CP is incorporated
predominantly as two-ring ‘disks’ during elongation towards the
5′ RNA terminus (illustrated schematically in Fig. 1A), while
elongation towards the 3′ terminus employs smaller aggregates.atic representation of TMV CP reassembly onto RNA containing the origin of
nse RNA transcripts employed as scaffolds; TMV genomic RNA and SFV lacZ
icrographs of the reassembly product obtained when the transcripts in panel B
1 CP. (D) TMV genomic RNAwith RGD CP. (E) SFV β-gal transcript with the
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of elongation is independent of RNA sequence (Turner et al.,
1988). This feature permits the engineering of RNA sequences
that can be efficiently assembled in vitro. We introduced the
TMV Oa into a SFV vector lacking the SFV structural proteins
and expressing the beta-galactosidase (β-gal) reporter gene
(SFV β-gal). Transcripts from this vector generated an RNA
replicon of approximately 13.6 kb, over twice the length of the
TMV genome (Fig. 1B). Because this RNA does not express
SFV structural proteins, it is movement-deficient but can
efficiently replicate in animal cells. We combined SFV β-gal
transcript and control TMV genomic RNAwith either wild-type
U1 CP or CP preparations generated from recombinant TMV
peptide fusions (Table 1). When wild-type U1 CP was combined
with TMV genomic RNA, we observed rods that were visually
indistinguishable from TMV by electron microscopy (Fig. 1C).
Although a distribution of lengths was present in the observed
population, rods of the expected length (300 nm) predominated.
Replacing the U1 CP with RGD CP, displaying the RGD-
integrin binding motif that mediates viral cell entry (Magnusson
et al., 2001), yielded a comparable reconstituted virion
population (Fig. 1D), indicating that epitope addition did not
alter the CP's reassembly properties. In the case for the SFV β-
gal transcript, the observed pseudovirions were approximately
double the length of the TMV rods, as expected (Fig. 1E).
To further characterize the reassembly process, we monitored
the change in absorbance at 310 nm (OD310; proportional to
average rod length (Butler and Klug, 1971)) following CP
addition (Fig. 2A). For the combination of wild-type U1 CPwith
TMV genomic RNA, an initial rapid rise in absorbance occurred
during the first 15 min, followed by a more gradual asymptotic
increase towards the absorbance of the virus reference, with
virions present at the same molar concentration as the RNA
scaffold. After a 4-h incubation, the reassembly product, virus
control and genomic RNA alone were inoculated onto the local
lesion host N. xanthi (Fig. 2B). We have noted repeatedly that
isolated TMV genomic RNA generates significantly (20–50
fold) lower numbers of lesions relative to intact virus, as
previously observed (Fraenkel-Conrat and Singer, 1959). With
encapsidation, the lesion numbers were similar to the intactTable 1
Tobacco mosaic virus coat protein fusions and peptides employed
Designation Description Unproc
U1 Wild-type TMV U1 M SYS
RGD Integrin receptor fusion M SYS
LSB 1295.10/K TMV Lysine modified TMV M EPM
Designation Description Linker/
SPDP K TMV SPDP loaded K TMV Reacted
β-gal K TMV β-gal peptide loaded K TMV β-gal p
(a) For TMV U1 and TMV RGD, the N-terminal methionine was cleaved and the a
retained and acetylated. (c) When reacted with lysine, the MW of the sulfo LC SPD
present (311 Da) or not (202 Da).virus, providing a functional though qualitative assessment of
the reassembly products. Reassembly profiles and local lesion
numbers obtained with the RGD CP were comparable to the
wild-type U1 CP control (Figs. 2C and D) although the
asymptotic rise in OD appeared more gradual, indicating that
for this particular peptide fusion, the displayed epitope did not
negatively impact the reassembly properties of the CP.
We also sought to encapsidate RNAs with multiple CP-
fusion proteins in order to generate pseudovirions that displayed
multiple peptides on their surface. We accomplished this by
combining two different CPs in a staged format. Fig. 2E shows a
representative OD310 profile for this staged reassembly with the
RGD and U1 CPs. The RNA was initially combined with the
RGD CP at a 1:10 RNA to CP mass ratio, approximately half
the requirement for complete RNA encapsidation. After 30 min,
the majority of the free CP was exhausted and the absorbance
reached a plateau. Electron microscopy confirmed that the
capsids formed were incomplete, with only an estimated 2% of
the rods measuring 300 nm (data not shown). When the U1 CP
was added, its incorporation into the partially assembled capsids
resulted in a stepwise increase in absorbance that was not
observed in the control reaction where buffer alone was
employed. With TMV genomic RNA as the scaffold, the extent
of encapsidation could be determined qualitatively by the
recovery of viral infectivity. For the staged combinations, a
clear increase in lesion numbers was observed relative to
reactions where only the first CP was present (Fig. 2F) and from
electron micrographs, 35% of rods observed were full length
(data not shown).
For encapsidation reactions, we typically employed a 30%
excess of CP, similar to the 20–22:1 CP to RNA mass ratios
employed by others investigating wild-type virus reconstitution
(Fraenkel-Conrat and Singer, 1959; Stussi et al., 1969). To
determine if the rate and extent of encapsidation were
influenced by the CP concentration, the standard 24:1 ratio
was compared to reactions where the CP was doubled (CP:RNA
ratio of 48:1). With the increased CP levels, no change in the
absorbance kinetics was observed for either scaffold tested
(TMV genomic RNA or SFV β-gal) (Fig. 3A) indicating that
the rate of CP addition to the RNA was independent of CPessed sequence Molecular weight (Da)
Theoretical Actual
…WTSGPAT 17535.6 (a) 17534
…WTS AGSGRGDSGA GPAT 18425.5 (a) 18427.3
K SYS…WTSGPAT 18151.4 (b) 18151.6
peptide data Molecular weight (Da)
Theoretical Actual
SPDP MW (c) 202 Da or 311 Da 18353.5 18343.9
18462.5 18453.7
eptide MW ICPMYARV: 952 Da 19303.7 19297.8
djacent serine acetylated. (b) For LSB 1295.10, the N-terminal methionine was
P is dependent on whether the pyridine ring protecting the sulfhydryl group is
Fig. 2. Single and dual CP reassembly onto TMV genomic RNA. Reassembly over time was monitored by the change in absorbance at 310 nm and functionality of the
reassembly product was evaluated by the local lesion assay. (A/B) Reassembly with wild-type U1 CP at a 1:24 RNA to CP mass ratio. (C/D) Reassembly with RGDCP
at a 1:24 RNA to CP mass ratio. (E/F) Reassembly of two unique TMVCPs onto a single RNA scaffold in a staged format. TMV genomic RNAwas combined with the
RGD CP at a mass ratio of 1:10 (50% requirement for encapsidation) and following a 30-min incubation an equal quantity of wild-type U1 CP or buffer was added. For
the ordinate, the OD for the CP alone controls was subtracted from the corresponding reassembly OD profile. Legend; RNA, genomic RNA alone; virus, TMVat the
same molar concentration as the genomic RNA in the reassembly reactions; CP, coat protein. For the local lesion assay, the mean and standard deviation for 3 leaf
inoculations are reported.
324 M.L. Smith et al. / Virology 358 (2007) 321–333concentration. However, since absorbance is proportional to
average rod length, the final OD310 at which the SFV β-gal
transcript plateaued was greater than for the 6.4 kb TMV
genomic RNA. In the case of TMV reconstitution, rod
elongation was essentially complete after 90 min and the
absorbance remained constant thereafter. For the SFV β-gal
transcript, the absorbance continued to increase and after 3 h
had not yet reached its plateau. For vaccine preparation,
encapsidations were therefore left overnight (∼16 h) to permit
capsid formation to reach completion. The size difference
between the two RNA scaffolds was readily evident by TPE
agarose gel electrophoresis (Fig. 3B), with TMV U1 virion used
as the reference. TMV migrated as a doublet, consisting of a
prominent well-defined band (*) and a less intense upper band
(**), likely representing virus particles associated end-to-end.
Virus reconstituted from TMV genomic RNA and U1 CP co-
migrated with the TMV U1 control, while pseudovirus
generated by the combination of SFV β-gal transcript with
U1 CP formed a distinct band that migrated just below the
presumed end-to-end rod band in the TMV U1 control. No band
was present when either the CP or RNA scaffold alone was
analyzed.
A prerequisite for the use of recombinant TMV CP for the
encapsidation of Oa-containing RNA is the ability to isolate
reassembly competent CP from purified virus, which is free
from RNA contamination. Our experience with over 10
different CP fusions indicated that certain epitopes were
incompatible with CP isolation by the acetic acid procedure
(Fraenkel-Conrat, 1957). TMV CP has a characteristic UV
absorption profile, with a reported maximum to minimumabsorbance ratio of 2.5 or greater (Fraenkel-Conrat, 1957). In
our hands, wild-type U1 CP had an absorbance ratio of 2.2–2.4
and for the CP fusions listed in Table 1 and successfully
employed for transcript encapsidation (Figs. 1–3), the ratio was
2.0 or greater. CPs that failed to reassemble had ratios of 1.0 to
1.8 suggestive of RNA contamination. Alternative chromato-
graphic procedures developed to separate the CP from RNA
(Durham, 1972) were considered, but these either gave poor
recoveries or were ineffective as the CP elution characteristics
were altered by the epitope displayed (data not shown).
Furthermore for certain epitopes, CP with the desired
absorbance ratio was recovered but aggregated and precipitated
when adjusted to 0.1 M phosphate for reassembly.
Since the display of epitopes on the pseudovirion surface as
genetic fusions may be limited by the ability to isolate the
recombinant CP, chemical conjugation of peptides to the surface
of reassembly products was also considered. For this approach,
LSB 1295.10 CP, which has a single surface exposed lysine
(Smith et al., 2006) and is capable of self-assembly, was
employed. A CD8+ epitope of β-gal (Oukka et al., 1996) was
conjugated to pseudovirions composed of TMV RNA or SFV
β-gal RNA encapsidated with LSB 1295.10 CP (Fig. 4). The
reassembly product was initially reacted with SPDP and mass
spectrometry confirmed reaction with essentially all the CP
residues (Fig. 4A) with the expected mass increase obtained
(Table 1). Peptide was then added to the activated recombinant
TMVor pseudovirion for loading via a disulfide bridge and the
extent of peptide loading assessed by protein gel electropho-
resis. Relative to the starting CP, β-gal peptide addition reduced
the amount of pseudovirus monomer (arrow) by approximately
Fig. 4. Peptide conjugation to lysine-modified TMV CP capsids. (A) MALDI-
Tof spectra for heterobifunctional linker SPDP conjugated 1295.10 CP. SPDP
increasesCPmass by 313.1 or 203.2Da (see Table 1) (B) SDS-PAGE analysis for
the conjugation of a cysteine containingβ-gal derived peptide (β-gal) to 1295.10
virus (K TMV) or 1295.10 CP encapsidated SFV β-gal transcript (K SFV β-gal)
via the SPDP linker. Arrow, indicates the CP monomer band; *, peptide loaded
CP monomer; **, CP dimer. (C) MALDI-Tof spectra for peptide addition to
SPDP activated LSB 1295.10 CP (see Table 1).
Fig. 3. Characterization of TMV CP reassembly onto Oa-containing RNA
scaffolds. (A) Comparison of the reassembly OD 310 nm kinetic profiles for
wild-type U1 CP combined with TMV genomic RNA or SFV β-gal transcript.
Both RNA scaffolds were employed at the same mass concentration and the CP
was added at either a 24-fold or 48-fold mass excess. (B) Comparison of the
migration rates for reassembly products generated from the 24:1 mass ratio CP:
RNA combinations in panel A on Coomassie-stained 0.5% TPE agarose gels,
relative to the migration of TMV U1. *, TMV virion band, **, putative TMV
rods associated end-to-end.
325M.L. Smith et al. / Virology 358 (2007) 321–33350%, as determined by densitometry (Fig. 4B). Aweak band (*)
corresponding to the addition of a single peptide was detected,
the identity of which was confirmed by MALDI-Tof (Fig. 4C
and Table 1). The majority of the conjugated species migrated
as a putative CP dimer (**), although the mechanism of dimer
formation was unclear.
In vitro testing of the SFV β-gal/TMV CP encapsidated
pseudovirus particles
The functionality of the pseudovirus particles was initially
tested in vitro using BioTrek-mediated uptake in baby hamster
kidney (BHK21) cells. After 24 h, expression of β-galactosi-
dase was observed (Figs. 5A and B), demonstrating that
following facilitated uptake by the cells the pseudovirion was
effectively uncoated, replicated and the reporter gene translated.
To confirm that naked transcript, which may have been present
in the encapsidated SFV β-gal preparations was not responsible
for the observed staining, cells were also incubated with RNA
alone. No significant β-gal staining in these negative controls
was observed, even when the transcript was present in a 10-fold
excess relative to the amount of experimental encapsidated SFV
β-gal RNA (Fig. 5C). This result indicates that only TMV CP
encapsidated SFV β-gal was translocated into the cells. For invivo studies, encapsidated transcript was prepared and stored at
−20 °C, with aliquots removed for each of the immunizations.
To confirm that the pseudovirions remained functional after
−20 °C storage, we performed a stability study over a 3-month
period, by incubating thawed aliquots with BHK21 cells and
staining for β-gal activity (Fig. 5D). An approximately
equivalent number of cells were positive for β-gal protein
expression indicating that no decline in potency occurred with
storage. Testing was also performed with 1295.10 CP-
encapsidated pseudovirus decorated with peptide (ICPMYARV;
Table 1). The level of staining was unaffected (data not shown),
indicating that SPDP conjugation and peptide loading did not
alter the disassembly and transcription properties of the vector.
Comparison of U1 CP and RGD CP encapsidated SFV β-gal in
vivo
To determine the ability of encapsidated SFV β-gal RNA to
elicit immune response, we encapsidated SFV β-gal RNAwith
either the U1 or RGD CPs. A 20 μg unadjuvanted dose of
pseudovirus (1 μg SFV β-gal RNA) was administered, with
serum samples taken following the third and fourth
Fig. 5. Evaluation of TMV CP encapsidated SFV β-gal vector functionality and stability in vitro. Encapsidated transcript or RNA alone was combined with the protein
translocation reagent BioTrek and incubated with BHK-21 cells that were subsequently stained for β-gal activity. (A) 25 ng SFV β-gal transcript encapsidated with U1
CP (0.5 μg reassembly product on a protein basis). (B) 100 ng SFV β-gal transcript encapsidated with 1295.10 CP (2 μg of reassembly product on a protein basis). (C)
Negative control; 1000 ng of unencapsidated SFV β-gal transcript. (D) Stability testing of 1295.10 CP encapsidated SFV β-gal transcript with storage at −20 °C. Mean
and standard deviation for 6 replicate wells at each timepoint are reported.
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antibodies against β-galactosidase were detected following
the fourth immunization although levels were 100–1000 fold
lower than the average response observed in mice that received
25 μg doses of β-gal protein (Fig. 6A). In contrast to
pseudovirion, administration of 1 μg naked SFV β-gal RNA
failed to elicit a measurable response and this was also the case
for repeated immunization with 100 μg plasmid DNA. When
the U1 CP was replaced with the RGD CP, no significant
improvement in the humoral immune response was observed
(data not shown). One animal from each group was immunized
a fifth time and after 5 days we evaluated T-cell responses by
IFNγ ELIspot. As shown in Fig. 6B, animals immunized with
the DNA plasmid or the encapsidated SFV β-gal transcript
showed a significant T-cell activation response, while no
response was observed after β-gal protein immunization. Fig.
6B also suggested that there was limited benefit, in terms of
T-cell activation, to encapsidation with the RGD CP. Based
on this and the humoral response data, evaluation of the RGD
CP in vivo was not pursued further.
Ability of encapsidated SFV β-gal to prime β-gal protein
immunization
Next, we tested the ability of pre-immunization (or priming)
with SFV β-gal to boost the immune response to a single dose
of β-gal protein (Table 2). With a single pseudovirion prime
(Fig. 7A; groups 2-2 and 2-4), only animals receivingpseudovirion 2 weeks prior to the protein boost had significant
antibody titers (group 2-4) relative to the PBS control (group 2-
1), while a naked RNA prime was ineffective (groups 2-5 and 2-
6). Therefore, both priming schedule and encapsidation of the
RNA transcript were critical for a humoral response. With the
administration of pseudovirion twice (group 2-3), the mean
antibody titer was increased 50-fold relative to the single
immunization. Cellular responses were also measured in two
mice per group 10 days after the protein boost (Fig. 7B). Only
animals receiving two doses of pseudovirion prior to the β-gal
boost (group 2-3) showed a statistically significant response
relative to the control (group 2-1).
Immunogenicity of SFV β-gal pseudovirion displaying a β-gal
CTL peptide
Encapsidation of SFV β-gal by LSB 1295.10 CP permits the
display of proteins or peptides on the capsid surface through
chemical conjugation (Fig. 4) that could potentially modulate
and/or augment the immune response elicited by the RNA.
Rather than a prime-boost regime, with RNA and protein admi-
nistered separately, we evaluated pseudovirion with a CD8+
CTL peptide conjugated to the TMVCP, which should boost the
same Kb restricted β-gal peptide encoded by the encapsidated
SFV vector (Table 3; groups 3-5 and 3-6). To distinguish
between contributions from the RNA and conjugated peptide to
the humoral and cellular immune responses, pseudovirion
lacking peptide (groups 3-3 and 3-4) and peptide conjugated to
Fig. 6. Humoral and cellular immune responses to the SFV β-gal transcript
encapsidated with either U1 or RGD CP. Groups of five mice were employed
and the high and low responders from each group were omitted for the humoral
response analysis. (A) Antibody response against β-galactosidase, for animals
administered 20 μg U1 CP encapsidated SFV β-gal transcript (U1/SFV β-gal;
1000 ng RNA). The average responses (Ave) for the groups receiving DNA
(100 μg), RNA transcript alone (1000 ng) or β-galactosidase protein (25 μg) are
also plotted. (B) Comparison of IFNg response following peptide stimulation.
Mean and standard deviation for 12 replicate wells for each group are reported.
The SFV β-gal RNA encapsidated with RGD CP (RGD/SFV β-gal) was
administered at 20 μg protein per dose.
Fig. 7. Humoral and cellular immune responses for TMV U1 CP encapsidated
SFV β-gal transcript employed in a prime/boost regime with β-galactosidase
protein. The vaccine schedules for each group are summarized in Table 2. (A)
Anti-β-galactosidase response in bleeds taken 8 days following the final
immunization. Groups of five mice were employed and the high and low
responders from each group were omitted in the analysis. Averages and standard
deviations for each group are plotted. *, indicates the average response was
statistically different from group 1; pV0.0476. (B) T-cell responses observed
with each immunization schedule. Following the final immunization, spleen
cells were harvested from two animals in each group and ELIspot analysis
performed. Mean and standard deviation for 12 replicate wells for each group
are reported. *, indicates the average response was statistically different from
group 1; p<0.0001.
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controls. Following the final immunization, pan IgG and IgG2
antibody titers were measured to assess the overall humoral
immune response and the prevalence of Th1 type T-help during
B-cell stimulation (Figs. 8A and B). As expected, β-gal peptideTable 2
Study design for the evaluation of SFV β-gal RNA in an encapsidated vector
prime/protein boost schedule
Group Immunization schedule #
mice/
group
#1 #2 #3
2-1 PBS PBS 25 μg β-gal protein 5
2-2 20 μg U1/SFV
β-gal
– 25 μg β-gal protein 5
2-3 20 μg U1/SFV
β-gal
20 μg U1/SFV
β-gal
25 μg β-gal protein 5
2-4 – 20 μg U1/SFV
β-gal
25 μg β-gal protein 5
2-5 1 μg SFV β-gal – 25 μg β-gal protein 5
2-6 – 1 μg SFV β-gal 25 μg β-gal protein 5
U1/SFV β-gal, U1 coat protein encapsidated transcript; SFV β-gal, transcript
alone.conjugated to the lysine modified TMV did not elicit antibody
titers above background levels (PBS immunization; group 3-8),
as the epitope displayed was a T-cell activation target. For the
SFV β-gal pseudovirus, pan IgG was detectable with two
immunizations and a strong IgG2 response was also observed,
suggesting active T-help. However, unexpectedly, when the
peptide and RNA components were combined the antibody
response was severely blunted following two immunizations
and was completely abrogated with administration of the third
dose (Fig. 8B, 3.5 and 3.6).
In Fig. 8C, the cellular responses obtained following two
immunizations are compared. The peptide conjugated to LSB
1295.10 TMV elicited significant levels of T-cell activation,
with approximately 600 per 106 IFNγ secreting cells detected
(group 3-1). In contrast the level of T-cell activation obtained
with encapsidated SFV β-gal was approximately 7-fold lower
Table 3
Study design to evaluate the immunogenicity of encapsidated SFV b-gal transcript decorated with a T-cell restricted β-gal peptide
Group Antigen dose and composition Immunization schedule #
mice/
group
TMV Encapsidated transcript/transcript #1 #2 #3
CP RNA
3-1 25 μg β-gal K – – x x 4
3-2 25 μg β-gal K – – x x x 3
3-3 – 25 μg K SFV β-gal ET x x 4
3-4 – 25 μg K SFV β-gal ET x x x 3
3-5 – 25 μg β-gal K SFV β-gal ET x x 4
3-6 – 25 μg β-gal K SFV β-gal ET x x x 3
3-7 – – 10 μg SFV β-gal x x x 3
3-8 PBS – – x x x 3
β-gal K, β-gal peptide decorated LSB 1295.10 CP or TMV; SFV β-gal, RNA transcript; K, LSB 1295.10 CP; ET, encapsidated transcript. Immunization schedule; x
indicates dose administration.
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6 and 7). Decoration of the SFV β-gal capsid with peptide
augmented the cellular response by approximately 50% relative
to peptide alone (group 3-5) and the increase observed was
statistically greater than the individual peptide and RNA
contributions (3.1+3.3; theoretical value). With the third
immunization, this differentiation was not maintained and the
responses to the peptide with and without SFV β-gal were
comparable (data not shown). In parallel with the bifunctional
pseudovirus testing, a high dose RNA immunization schedule
was also evaluated (group 3-7). SFV β-gal RNA was
administered at a 10 μg dose, 10-fold higher than previously
tested, in order to determine the extent of the immunological
response elicited by unencapsidated RNA vector alone. At the
higher dose, we observed both humoral and cellular immune
responses following three immunizations (Fig. 8A, group 3-7;
Fig. 8D). However, the mean antibody titers were 2–4-fold
lower and T-cell activation 2-fold lower relative to immunization
with the encapsidated SFV β-gal (group 3-4), where transcript
dose was 1.25 μg. Therefore, encapsidation of RNA improved
vector efficiency, as measured by increased levels of humoral
and cellular immune responses to SFV-produced protein, while
permitting transcript dose to be reduced by at least 8-fold.
Discussion
To our knowledge, this is the first demonstration in vivo of
the uptake and replication of a plant virus CP-encapsidated
animal RNA virus vector. The ability to efficiently encapsidate
RNAs of interest with a plant virus CP could offer a safer
alternative to current animal RNA virus encapsidation strate-
gies. The CP of TMV can accept small (generally up to 25
amino acid) peptide fusions with multiple reports showing the
utility of TMV in vaccine applications, through the display of
neutralizing epitopes (reviewed in Pogue et al., 2002). Recently
we described a methodology for the display of whole proteins
on the surface of TMV (Smith et al., 2006) and have also shown
that TMV displaying T-cell epitopes can elicit a strong cellular
immune response, capable of protecting mice against tumor
challenge (McCormick et al., 2006). Disassociating the
recombinant TMV particles and isolating free, reassemblycompetent CP, which either displays an immunologically
relevant peptide or has been modified to accept peptides/
proteins via chemical conjugation opens the possibility of
generating bifunctional pseudovirions composed of comple-
mentary protein and nucleic acid components. Employing both
wild-type and recombinant CPs, the successful encapsidation of
the 13.6 kb TMV Oa SFV β-gal transcript was confirmed by
electron microscopy (Fig. 1) and the kinetics of reassembly
compared with TMV genomic RNA as the scaffold (Fig. 3). To
demonstrate dual CP virion formation, sequential CP addition to
the RNA transcript was performed and we were able to observe
the staged addition of the capsid by the OD310 as well as the
recovery of infectivity by the local lesion assay (Figs. 2E and F).
From electron micrographs, an estimated 35% of the bivalent
encapsidated pseudovirus were full length (data not shown)
indicating further optimization to improve yield is possible. We
were also able to obtain pseudovirions with tailored surface
compositions by mixing two CP preparation before the addition
of the RNA scaffold (data not shown).
To evaluate improved cellular uptake with the RGD CP
fusion, SFV β-gal encapsidated transcripts were incubated with
BHK21 cells, which express integrin αvβ3, the receptor for the
RGD cell-binding motif (Alcala et al., 2001). However, testing
in the absence of the BioTrek protein translocation reagent
showed no intracellular β-gal expression (data not shown),
indicating no measurable pseudovirion internalization. One
possibility is that particle size may play a role. RGD has been
employed successfully in the context of soluble proteins (Alcala
et al., 2001) and icosahedral capsids (Magnusson et al., 2001)
with diameters less than 100 nm, whereas the rod-like SFV β-
gal capsids were approximately 600 nm in length and possibly
too large to facilitate receptor meditated uptake. However, once
internalized with the aid of the BioTrek reagent, reporter gene
expression was obtained, demonstrating that a plant CP capsid
can be efficiently disassembled within a mammalian cell to
allow RNA replication and translation (Fig. 5). Furthermore, the
SFV β-gal encapsidated by U1 CP was immunogenic (Figs. 6–
8) and therefore successfully internalized and processed by
immune effector cells. The humoral (data not shown) and
cellular immune responses (Fig. 6B) elicited by RGD CP
packaged transcript were comparable to U1 CP encapsidation,
Fig. 8. Humoral and cellular immune responses for encapsidated SFV β-gal
transcript decorated with a β-gal derived CTL epitope. The experimental design
and group designations are outlined in Table 3. (A and B) Pan IgG and IgG2
serum antibody responses against β-galactosidase 8 days following the final
immunization. Averages and standard deviations for each group are plotted. (C)
T-cell responses observed in the subset of groups that received two
immunizations. Following the final immunization, spleen cells were harvested
from 4 animals in the selected groups and ELIspot analysis performed. *,
response in group 3-5 was statistically different from group 3-1; p=0.0026. **,
response in group 3-5 was statistically different from the theoretical sum of the
responses from groups 3-1 and 3-3; p=0.042. (D) Comparison of T-cell
response after three immunizations for the 10 μg transcript dose (3–7) with the
response obtained from 8-fold less encapsidated transcript (3–4). For the
ELIspot analysis, mean and standard deviation for 12 replicate wells for each
group are reported.
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uptake by phagocytic and/or endocytic mechanisms was
sufficient and obviated the need for cell fusion motifs. This
in vivo data are in agreement with our previous observation
of spontaneous and efficient wild-type U1 TMV uptake byeither isolated spleen or bone marrow cells (McCormick et al.,
2006).
When immunization with SFV β-gal alone was compared to
encapsidated transcript administered at equivalent nucleic acid
doses (Figs. 6 and 7), encapsidated transcript repeatedly
produced superior humoral immune responses, with no anti-
β-gal detected in the sera of animals vaccinated with RNA
alone. By increasing the free transcript dose, cellular and
humoral immune responses were obtained (Fig. 8); however,
both antibody titers and activated CD8+ T-cell numbers were
notably higher with a significantly lower dose of encapsidated
SFV β-gal, indicating that particulate antigen uptake is an
effective mechanism for RNA vector delivery. These results are
consistent with those from several groups that have directly
compared transcript with recombinant SFV particles (Anders-
son et al., 2001; Berglund et al., 1999; Brand et al., 1998;
Fleeton et al., 2000; Zhou et al., 1994, 1995). It would therefore
be interesting to compare the pseudovirions created in this study
with the SFV transcript encapsidated by its native CP, to
evaluate how a heterologous CP impacts nucleic acid potency.
In addition, it would be informative to compare, through
histochemical staining, the localization of the TMV CP-
encapsidated vector with that of recombinant SFV particles
(Morris-Downes et al., 2001) and naked SFV RNA. Formative
early studies in rabbits demonstrated that owing to their
particulate structure, 14C-labeled TMV virions were rapidly
and effectively transported from the site of injection to proximal
lymph nodes, and then to the spleen (Loor, 1967).
At a dose of 1000 ng naked transcript, we were unable to
obtain T-cell activation. In contrast, others have reported that as
little as a single 100 ng RNA dose successfully elicited a CD8+
T-cell response (Ying et al., 1999). Ying et al. employed a similar
vector (lacking the Oa); however, the mouse strain/restricted
peptide combination (Balb/C/β-gal876–884 LPYLGWLVF) was
different to the current study and peptide restimulation prior to
IFNγ measurement was for 6 days, while we employed a
22-h stimulation, which limits the augmentation of the response
by cell proliferation. Genetic immunizations typically generate
low levels of antibodies, with more robust T-cell responses due
to intracellular expression and processing of the antigen. With
DNA immunization, appropriate class I peptide loading did
occur and was confirmed by the detection of activated IFNγ
secreting CD8+ T-cells following β-gal peptide stimulation
(Fig. 6B). No humoral immune response was observed, even
with the 100 μg dose; however, this may reflect the antigen
expressed (β-gal) rather than the mode of vaccination itself,
since we have employed a similar DNA vaccine expressing
green fluorescent protein and obtained an antibody response in
mice (data not shown). In the case of encapsidated SFV β-gal,
antibodies were detected, most likely due to β-gal escape from
cells expressing the reporter gene that had undergone apoptosis
and lysis (Ying et al., 1999). As expected, titers were
significantly lower than in animals immunized with β-gal
protein (Fig. 6A) indicating that effective priming was obtained,
but boosting was low due to reduced protein concentrations. In
an attempt to augment the immune response, we complemented
the nucleic acid prime with a single β-gal protein boost (Fig. 7)
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al., 1999; Soleimanjahi et al., 2006). We observed that effective
priming required the SFV β-gal to be encapsidated and that the
timing of the protein boost was also an important factor. By
priming twice with the encapsidated transcript, we were able
to further improve the humoral response and also elicit a CD8+
T-cell response. Overall, similar to previous studies that
demonstrate upregulation of both antibody and cellular
responses with nucleic acid priming and protein boosting, we
also see marked increases in both types of immune responses
when encapsidated SFV β-gal was employed.
One of the recombinant CPs proteins employed, LSB 1295.10,
was engineered with a surface exposed N-terminal lysine. Lysine
is compatible with numerous commercially available linkers
permitting the co-delivery of proteins or peptides with the
encapsidated transcript. In the present study, a β-gal CTL
restricted peptide was combinedwith theβ-gal nucleic acid signal
encoded by encapsidated SFV RNA to generate a bifunctional
pseudovirion (Fig. 8).We hypothesized that inclusion of a surface
fused peptidewould provide complementary protein boosting and
improve T-cell activation over that generated fromRNA transcript
alone. When a β-gal peptide fused to TMV was administered,
potent T-cell activation was observed, and the response was
notably superior to encapsidated β-gal RNA. T-cell stimulation
was improved still further with the bifunctional pseudovirion and
the response observed was significantly greater than the
theoretical combined value for the peptide and the RNA given
as single agents (Fig. 8C). The superior T-cell response obtained
with the conjugate vaccine relative to pseudovirion suggests that
the quantity of peptide delivered via CP unloading may exceed
that generated by RNA translation and subsequent β-gal
proteolysis. Alternatively, the conjugate vaccine may deliver
peptide antigen more rapidly, resulting in better antigen
presentation to dendritic cells as compared to long-term low-
level antigen delivery by RNA translation.
An unexpected consequence of the bifunctional pseudovir-
ions was a downregulation of the humoral immune response,
with no circulating β-gal specific antibodies detected after three
immunizations. Animals receiving the encapsidated transcript
lacking peptide showed good humoral responses suggesting that
the potent stimulatory properties of the peptide may have
skewed the immune response to T-cell activation. For some
vaccine strategies, a highly desirable outcome is the control the
Th1/Th2 response to immunization. For example, an early
formalin-inactivated vaccine composition for the prevention of
respiratory syncitial virus induced a Th2-type antibody response
that exacerbated disease characteristics in some children, and
was subsequently withdrawn (reviewed in Piedra, 2003).
In summary, these data support the observation that
encapsidated RNA can augment antigen-specific immune
responses, and this concept will be explored further in ongoing
studies. The ability of this system to present both peptide
antigens and intact proteins through a combination of CP fusion
and SFV vector expression provides for flexibility in vaccine
design. Through both genetic fusion and chemical conjugation,
one or multiple antigens can decorate the pseudovirion capsid,
and the response to these surface displayed immunogens can beenhanced and/or skewed by the co-expression of the same
antigen (as presented here), or by expression of immunomod-
ulatory proteins such as cytokines from the SFV replicon. With
regard to the potential for scale-up, we have successfully
modified the original coat protein isolation procedure (Fraenkel-
Conrat, 1957) to isolate up to 6 g of reassembly competent coat
protein on a laboratory scale, and believe that further scale-up is
possible. In parallel, improved processes are being developed for
large-scale capped RNAs synthesis, including batch-fed meth-
odologies that increase the yield of RNA synthesis by 5- to 6-
fold under current Good Manufacturing Practices (cGMP;
Emmanuel Labourier, Asuragen Inc., personal communication).
Linking best-mode technologies will support the further
development of this new vaccine platform.
Materials and methods
RNA scaffold vector construction
The SFV β-gal vector (Fig. 1B) was generated by introducing
the TMV origin of assembly (Oa) 3′ of the lacZ gene in the
pSFV3-lacZ vector (Invitrogen, Carlsbad, CA). The TMVOawas
amplified by PCR from plasmid p801 (Dawson et al., 1986),
containing the full length cDNA of TMV U1, by standard
techniques. The resulting PCR product of about 315 bp was
digested with XmaI and ligated into XmaI digested pSFV3-lacZ.
Clones with the correctly oriented TMV Oa fragment were
identified by sequencing. To obtain SFVβ-gal transcript, the SpeI
linearized vector was purified using a Zymo-spin column (Zymo
Research Corporation, Orange, CA) and transcribed with SP6
RNA polymerase using the SP6 mMessage mMachine kit
(Ambion, Austin, TX), according to the manufacturer's instruc-
tions. The RNAwas isopropanol precipitated prior to encapsida-
tion. For instances where TMV genomic RNA was used as the
scaffold, the RNAwas isolated from purified wild-type U1 TMV
using a Qiagen RNeasy kit (Valencia, CA).
Cloning, expression and purification of the TMV coat protein
fusions
The amino and carboxy termini of the TMV CP reside on the
exterior of the TMV capsid, allowing amino acid fusions in
either location to be displayed on the virion surface. A series of
lysine-modified TMVs were generated (Smith et al., 2006) and
from this series LSB 1295.10 (Table 1) was selected based on
the level of SPDP conjugation obtained, relative to the other
constructs evaluated (data not shown). For the TMV CP fusion
displaying the integrin fusion receptor (Magnusson et al., 2001),
standard molecular techniques were used to fuse the amino acid
sequence SGRGDSG to the 3′ end of the TMV CP ORF, in a
plasmid containing the full-length cDNA clone of TMV RNA,
under the control of the T7 RNA polymerase promoter. The
RGD peptide was located 4 amino acid from the native carboxy
terminus and bounded by the linker amino acids AG and A that
were introduced by the cloning strategy used (Table 1; RGD).
Infectious transcripts of each clone were generated with T7
polymerase from the respective DNA plasmid, using the
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turer's instructions. Nicotiana benthamiana plants were inoc-
ulated and recombinant TMV purified from systemically
infected N. benthamiana as previously described (Smith et al.,
2006). In the case of wild-type TMV U1, previously isolated
virion was employed as inoculum and Nicotiana tabacum (cv.
MD609) replaced N. benthamiana as the host.
Analytical procedures, immunoassays and electron microscopy
Polyacrylamide gel electrophoresis (PAGE) was performed
on 10–20% Tris glycine gels (Invitrogen), following the
manufacturer's instructions. For gel analysis by densitometry,
a GS810 calibrated densitometer in conjunction with the
Quantity 1 software (both BioRad) was used. The Mark 12
protein standard (Invitrogen) was employed as molecular weight
reference. Encapsidated transcripts were analyzed by Tris/
Phosphate/EDTA (TPE) agarose gel electrophoresis (Sambrook
et al., 1989). Samples were resuspended in DNA gel loading dye
(Promega, Madison, WI) and electrophoresis was performed at
150 mA for 2–3 h, with the 0.5% w/v agarose gels and buffer
chilled to 4 °C prior to use. Agarose gels were stained overnight
in 10% v/v glacial acetic acid/40% v/v ethanol containing 0.1%
w/v Coomassie brilliant blue R-250 and destained using the
same buffer lacking dye. Protein quantitation was performed
using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL)
in a microtiter plate format following the manufacturer's
instructions. Protein mass determination was performed by
matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF MS). The increase in infectivity,
following encapsidation, for reassembly reactions that employed
TMV genomic RNA as a scaffold, was evaluated on the local
lesion host N. tabacum cv. xanthi (N). For electron microscopy,
grids (400Mesh copper, carbon coated; Ted Pella, Bedding, CA)
were floated on drops of encapsidated transcript and negatively
stained with 1% phosphotungstic acid. The MALDI-TOF MS,
local lesion assay and electron microscopy grid preparation are
described in greater detail elsewhere (Smith et al., 2006).
Preparation of free TMV coat protein
The wild-type or recombinant virus preparations were diluted
to 1 mg/ml and treated with powdered activated carbon (Norit,
Marshall, TX) at 1% w/v with stirring for 1 h at 4 °C. Following
centrifugation (10,000×g for 10 min) to remove the activated
carbon, the virus was concentrated to 10–20 mg/ml by PEG
precipitation, prior to virus disassociation by acetic acid (Fraenkel-
Conrat, 1957). CP preparations were stored at 4 °C in the presence
of 0.02% w/v sodium azide and were confirmed RNA free when
no local lesions were detected following inoculation onto the local
lesion host at a minimum protein concentration of 2 mg/ml.
Reassembly of TMV coat protein onto Oa-containing RNA
scaffolds
In reassembly reactions, the RNA scaffold and CP were
combined at a mass ratio of 1:24 or 1:48, the former ratiocorresponding to a 30% molar excess of CP. Final RNA and CP
concentrations were confirmed by gel electrophoresis for both
the reassembly reactions and controls. During encapsidation,
appropriate precautions were taken to ensure that all buffers and
labware were ribonuclease-free. Prior to use, the CP was
dialyzed against 0.1 M phosphate pH 7.0 at 4 °C, centrifuged at
20,000×g for 30 min to remove any precipitate that formed and
pre-equilibrated for 36 to 48 h at room temperature, to permit 20
S disk formation (Durham and Klug, 1971). The RNA scaffold
was diluted in phosphate buffer to a final buffer molarity of
0.1 M and the equilibrated CP added to give a final RNA
concentration of 50 μg/ml. The reassembly reactions were
allowed to proceed for 3–4 h (TMV genomic) or overnight (SFV
β-gal transcript) and when required, the encapsidation products
recovered by 4% w/v PEG precipitation in the presence of 4%
w/v NaCl. To monitor the reassembly process by absorbance at
310 nm (Butler and Klug, 1971), the reactions and controls were
placed in a 96-well polystyrene plate (Nalge Nunc, Rochester,
NY) and the increase in absorbance tracked using a 96-well
plate spectrophotometer (Molecular Devices, Sunnyvale, CA).
Chemical conjugation of peptides to lysine modified capsids
Conjugation reactions were performed with purified LSB
1295.10 virion or LSB 1295.10 CP encapsidated SFV β-gal
transcript. To permit peptide loading, the virion/encapsidated
transcript was combined with a 20-fold molar excess of sulfo LC-
SPDP (Pierce) in PBS containing 5 mM EDTA and incubated for
4 h at room temperature. Unreacted heterobifunctioal linker was
removed by dialysis and theβ-gal peptide (ICPMYARV) added at
a 10-fold molar excess. The conjugation reactions were incubated
with end-to-end rotation at room temperature, for 16 h. Free
peptide was removed by dialysis and peptide conjugation
confirmed byMALDI-TOFMS. The percentage of CP displaying
the β-gal peptide was estimated by densitometry for PAGE
performed under non-reducing conditions.
In vitro testing of SFV β-gal encapsidated vectors
The functionality of the SFV β-gal encapsidated vectors was
evaluated in vitro. BHK-21 cells (plated at 2×104 cells/well 24 h
prior to testing) were incubated with 0.5–2 μg of freshly prepared
pseudovirus particles on a protein basis (25–40 ng transcript)
combined with the protein translocation reagent BioTrek (Strata-
gene, La Jolla, CA). After a 3–4-h incubation, the cells were
washed and incubated a further 18 h in complete DMEM media
with 20% fetal bovine serum. The cells were then washed and
stained for beta-galactosidase activity with the X-gal staining kit
(Invitrogen). Stained cells were counted using an ELIspot reader
(AID, Strassberg, Germany). Free SFV β-gal transcript (0.1–1 μg)
was used as a control and samples were tested in replicates of six.
Immunogenicity testing in mice and serological/cellular
response analysis
The murine studies were performed using 6–8 week old
female C57/b6 mice (Harlan Sprague–Dawley, Indianapolis,
332 M.L. Smith et al. / Virology 358 (2007) 321–333IN) that were housed at Antibodies Inc. (Davis, CA). The
reported doses for virion and encapsidated transcript (Tables 2
and 3) are based on protein as quantitated by the BCA assay.
The RNA dose per immunization corresponds to approximately
5% of the protein dose. When transcript alone was adminis-
tered, the reported dose was for RNA alone, as determined by
OD260. DNA immunizations employed the plasmid pcDNA3.1/
His/LacZ (Invitrogen) that expressed β-gal. Vaccine was
administered subcutaneously (s.c.) at 2-week intervals unless
otherwise noted and serum samples obtained by tail bleed, 8–
10 days post-immunization. The humoral immune response was
determined by enzyme linked immunosorbent assay (ELISA) as
previously described (Smith et al., 2006) with β-gal protein
coated at 5 μg/ml employed as the capture antigen. Anti-β-gal
titers reported in ng/ml were determined from a standard curve
generated by a 3-fold serial dilution of a 1000 ng/ml mouse anti-
β-gal monoclonal antibody (Promega). Serum endpoint dilu-
tions corresponded to an absorbance reading of twice that
obtained with pooled sera taken prior to the first immunization.
To evaluate the cellular response, spleens were harvested and
single cell suspensions generated. Cell plating on IFNγ
antibody coated plates, peptide stimulation, assay development
and counting of positive spots were performed as previously
described (McCormick et al., 2006). The β-gal derived C57b/6
restricted CTL epitope (ICPMYARV; Oukka et al., 1996) was
used for stimulation with an ovalbumin peptide (SIINFEKL;
Rotzschke et al., 1991) employed as a control. The peptides
(purity >95%) were synthesized by Biomer Technology
(Hayward, CA). Data and statistical analysis (unpaired t-tests)
were performed using GraphPad (version 4.0; San Diego, CA).
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